Cubist Systematic Strategies LLC decreased its holdings in Cryoport, Inc. (NASDAQ:CYRX - Free Report) by 60.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 108,037 shares of the company's stock after selling 167,321 shares during the quarter. Cubist Systematic Strategies LLC owned about 0.22% of Cryoport worth $841,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Avanza Fonder AB acquired a new stake in shares of Cryoport in the 4th quarter worth $64,000. Quarry LP acquired a new stake in shares of Cryoport in the 4th quarter worth $69,000. Nebula Research & Development LLC boosted its position in shares of Cryoport by 21.6% in the 4th quarter. Nebula Research & Development LLC now owns 12,442 shares of the company's stock worth $97,000 after purchasing an additional 2,207 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of Cryoport by 135.5% in the 4th quarter. Russell Investments Group Ltd. now owns 12,875 shares of the company's stock worth $100,000 after purchasing an additional 7,407 shares in the last quarter. Finally, Olympiad Research LP acquired a new stake in shares of Cryoport in the 4th quarter worth $103,000. Institutional investors and hedge funds own 92.90% of the company's stock.
Cryoport Stock Performance
Shares of CYRX stock opened at $6.47 on Thursday. The stock has a market cap of $324.39 million, a PE ratio of -1.91 and a beta of 1.92. The business has a 50-day simple moving average of $5.91 and a 200-day simple moving average of $6.86. The company has a quick ratio of 5.32, a current ratio of 5.70 and a debt-to-equity ratio of 0.48. Cryoport, Inc. has a 52-week low of $4.58 and a 52-week high of $14.21.
Cryoport (NASDAQ:CYRX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. The business had revenue of $41.04 million during the quarter, compared to analysts' expectations of $56.19 million. Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. On average, equities analysts expect that Cryoport, Inc. will post -0.99 EPS for the current year.
Insider Activity
In other news, CEO Jerrell Shelton sold 4,620 shares of the business's stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $6.29, for a total value of $29,059.80. Following the completion of the transaction, the chief executive officer now owns 765,399 shares of the company's stock, valued at $4,814,359.71. The trade was a 0.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders sold a total of 19,830 shares of company stock valued at $118,353 in the last quarter. 10.00% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
A number of analysts have commented on the company. Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 price target on shares of Cryoport in a research report on Thursday, May 8th. UBS Group lifted their price target on Cryoport from $10.00 to $11.00 and gave the stock a "buy" rating in a research report on Tuesday, April 1st. Roth Mkm reaffirmed a "buy" rating and set a $15.00 price target on shares of Cryoport in a research report on Tuesday, April 1st. Morgan Stanley lowered their price target on Cryoport from $8.00 to $7.00 and set an "equal weight" rating for the company in a research report on Monday, May 5th. Finally, Guggenheim reaffirmed a "buy" rating and set a $10.00 price target on shares of Cryoport in a research report on Wednesday, April 16th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $11.00.
Check Out Our Latest Report on CYRX
About Cryoport
(
Free Report)
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cryoport, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cryoport wasn't on the list.
While Cryoport currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
